The therapeutic landscape for NETs that have progressed after the use of somatostatin analogues is expanding after years of stagnation. Accompanying the emergence of peptide receptor radionuclide medicines and targeted therapy are a number of knowledge and competence gaps tied to their properties and positioning in evolving treatment algorithms. Additionally, while awareness of NETs is rising among oncology healthcare providers, clinically consequential misdiagnoses and diagnostic delays remain common to the detriment of those living with these malignancies. Through a mixture of small group and case-based education, oncologists, gastroenterologists, nuclear medicine specialists, and other ancillary clinicians working in community settings can increase their index of suspicion for NETs, better navigate the associated diagnostic workup, and gain familiarity with biomarkers that can inform treatment. Educational initiatives can additionally augment learners ability to integrate newer medicines into real-world, community practice settings and work collaboratively as members of multidisciplinary teams to determine the most appropriate sequence of medicines for patients with NETs. By having a better appreciation of the perspectives of professional colleagues and patients, oncology healthcare providers can ensure that those in their care achieve the best possible outcome.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 384 Inverness Parkway
Pricing
All courses included · from $18.75/mo
Courses are included in the subscription; some are also sold individually.
| Student Flex | $18.75/mo |
| Professional Flex | $60/mo |
| Student 3-Year | $100 |
| Student 2-Year | $112.50 |
+4 more plans
Collected from the provider’s public pages · source
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Maternal-Fetal Medicine
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurocritical Care
- Neurodevelopmental Disabilities
- Neurology
- Neuroradiology
- Nuclear Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Plastic & Reconstructive Surgery
- Practice Management & Ethics
- Pulmonary Disease
- Sleep Medicine
- Surgical Oncology
- Thoracic Anesthesia
- Urological Oncology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- includes Case-based learning
- Credit · Up to 1 credit
- Commercial Support
-
ReleasedSep 15, 2025
-
Last day to claim creditNov 1, 2026 3 weeks left
-
National Association for Continuing Education Neuroendocrine Tumors: Accelerating Diagnosis and Optimizing Multidisciplinary Care in a Rapidly Evolving Treatment Era
-
PRIME Education, Inc. (PRIME®) Mastering Recent Advances in Targeted Therapy for GEP-NETs
-
Learner’s Digest International (TM) Recent Advancements in Imaging and Treatment Options of Neuroendocrine Tumors
-
Plexus Communications +1 New Additions to the Neuroendocrine Tumor Treatment Arsenal: Essential Advances in Targeted Therapy & Nuclear Medicine
-
Plexus Communications +1 Transforming Care in Pancreatic Ductal Adenocarcinoma: Emerging Evidence and Clinical Implications
-
Plexus Communications +1 Advancing EGFR-Mutated NSCLC Management Across Practice Settings: Evidence-Based Approaches to Testing, Treatment Selection, and Sequencing
